StockNews.com Initiates Coverage on Eiger BioPharmaceuticals (NASDAQ:EIGR)

Equities research analysts at StockNews.com assumed coverage on shares of Eiger BioPharmaceuticals (NASDAQ:EIGR – Get Free Report) in a note issued to investors on Friday. The firm set a “sell” rating on the biotechnology company’s stock. Eiger BioPharmaceuticals Price Performance Shares of NASDAQ EIGR opened at $6.74 on Friday. The firm has a market cap […]

Leave a Reply

Your email address will not be published.

Previous post Bloom Energy Co. (NYSE:BE) Given Consensus Recommendation of “Moderate Buy” by Analysts
Next post Synovus Financial (NYSE:SNV) PT Raised to $46.00 at Keefe, Bruyette & Woods